Abstract:Purpose/Objective(s) Mucosal melanoma of the head and neck is a rare and deadly disease. The optimal treatment for mucosal melanoma remains uncertain, and there is no consensus on the most effective treatment approach, including the extent of surgical resection, the use of adjuvant therapy, and the role of immunotherapy. Current controversies and unknowns about disease treatment and outcomes stem from the rarity of mucosal melanoma, the lack of large-scale clinical trials, and the heterogeneity of the disease. This study aims to determine the survival benefit of immunotherapy, surgery and radiation in setting of mucosal melanoma. Materials/Methods We extracted data from NCDB database with histology codes (ICD-O 2 melanoma codes M872–M879) for patients with mucosal melanoma diagnosed from year 2000-2020 with a total sample size 3937. The patients’ characteristics were summarized by median and interquartile range (IQR) for a continuous variable and by frequency and percentage for a categorical variable. We considered the different combinations of treatments in terms of surgery, chemotherapy, radiation therapy, and immunotherapy. The outcome variables are (1) time to death since diagnosis, and (2) death. Kaplan-Meier survival estimates were used. The log-rank test was employed to compare the survival distributions of the different treatment groups. Cox Proportional Hazard Regression model was performed to evaluate the association between the treatment combinations and survival outcome, adjusting the clinical and demographic variables (e.g., sex, age, stage of cancer). Hazard ratio (HR) and 95% confidence interval (CI) were reported. Mortality rate for each treatment combination was also reported, and the multiple logistic regression model was used to examine the effect of different treatment on mortality. Results The median overall survival (OS) time for all patients diagnosed with mucosal melanoma was 25.7 months. Among them, 50.1% were males, 9.4% younger than 50 years old and 50.6% older than 70, 88.7% white, and 57.6% with Medicare. Cox proportional hazard model showed that the survival time is significantly associated with the following factors: age group 60-70 (HR 1.25, 95%CI [1.06, 1.48]) and >70 (HR 1.83, 95%CI [1.56, 2.13]) comparing with age group <50. Male sex increased the risk of death (HR 1.13, 95%CI[1.04, 1.22]). Surgery decreased the risk of death (HR 0.49, 95%CI [0.44, 0.55]). The use of radiation and immunotherapy had no association with survival. Chemotherapy increased the risk of death (HR 1.33, 95%CI [1.18,1.51]), and was associated with more advanced age and high tumor stage. The multiple logistic regression model showed similar impact of these factors on mortality. Conclusion Treatment paradigms for mucosal melanoma vary widely. Local therapy remains important for improved survival. Further analyses should be done to explore the benefits of multi-modality treatment.

Efficacy and Safety of Postoperative Adjuvant Radiation Therapy in Resected Nasal Cavity and Paranasal Sinus Mucosal Melanoma: A Combined Analysis.

808P Postoperative Adjuvant Radiotherapy Can Reduce the Local Recurrence of Nasal Cavity and Paranasal Sinus Mucosal Melanoma: A Prospective Design, Retrospective Analysis and Case–control Study

Oncological Outcome of Patients with Salivary Gland Cancer Treated with Surgery and Postoperative Intensity-Modulated Radiotherapy: a Retrospective Study

Postoperative Radiotherapy In Resected Sinonasal Mucosal Melanoma.

Impact of Adjuvant Therapy on Survival for Sinonasal Mucosal Melanoma

Endoscopic Surgery Combined Chemoradiotherapy and PD-1 Blockade in Patients with Sinonasal Mucosal Melanoma.

Impact of different surgical and postoperative adjuvant treatment modalities on survival of sinonasal malignant melanoma

Adjuvant radiotherapy plus systemic chemotherapy in resected head and neck mucosal melanoma.

Characteristics and prognosis of primary mucosal melanoma of nasal cavity and paranasal sinuses: a clinical analysis of 94 patients

Sinonasal Mucosal Melanoma Survival Outcomes, Recurrence Patterns, and Prognostic Factors: A Systematic Literature Review and Meta-analysis of Publications after 2000

Outcomes of Primary Mucosal Melanoma Originated from Sinonasal Tract

Efficacy Analysis of Endoscopic-Assisted Traditional Surgery and Traditional Surgery for Sinonasal Malignant Melanoma

Immunotherapy in the Management of Sinonasal Mucosal Melanoma: A Systematic Review

[Clinical Analysis and Literature Review of Primary Melanoma in Nasal Cavity and Sinus--report of 9 Cases].

Treatment and related morbidity of nasal cavity and paranasal sinus cancers

Preoperative Treatment for Marginally Resectable Metastatic Melanoma: A Single Center Experience in China.

Sinonasal mucosal melanoma in The Netherlands between 2001 and 2021: a clinical and epidemiological overview of 320 cases

Treatment of Stage III Resectable Melanoma—Adjuvant and Neoadjuvant Approaches

A combined microinvasive trans-submandibular and nasendoscopy surgical approach to dissect recurrent or radiotherapy-insensitive nasopharyngeal carcinoma

Clinicopathological Features and Prognosis of Sinonasal Mucosal Malignant Melanoma: A Retrospective Study of 83 Cases in a Chinese Population

Local Therapy in the Management of Mucosal Melanoma: An NCDB Analysis